LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, received a purchase order (“PO”) from Ethos Discovery for its exclusive MiQLab(TM). Designed for use in veterinary hospitals, MiQLab features an automated, easy-to-use system and rapid, in-hospital identification of pathogens. That information is invaluable for veterinarians as they make patient-care decisions. LexaGene’s MiQLab tests samples using real-time PCR, which is recognized for its sensitivity and specificity. “Up until now, veterinarians have had limited options for infectious disease testing,” said LexaGene CEO and founder Jack Regan, MD, in the press release. “Generally, veterinarians send collected samples to reference laboratories and wait up to 5 days or more to receive the results. This slow turn-around time and delay in proper treatment can be frustrating to many veterinarians and potentially harmful to their patients. With the MiQLab, we are changing veterinary diagnostics. Veterinarians will now have the opportunity to adopt an automated, rapid, in-hospital, reference laboratory quality testing solution so they can deliver world-class care. We are gaining traction by steadily building momentum with MiQLab in the veterinary market and are looking forward to meeting the demand and fulfilling orders in 2021.”
To view the full press release, visit https://ibn.fm/Ob6mX
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com.
NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork